Is radiation dose reduction the right answer for HPV-positive head and neck cancer?

Summary Patients with head and neck squamous cell carcinoma (HNC) related to human papillomavirus (HPV) represent a growing and distinct patient cohort with unique molecular and epidemiologic characteristics. These patients have markedly improved survival outcomes compared to those with traditional...

Full description

Saved in:
Bibliographic Details
Published in:Oral oncology 2014-06, Vol.50 (6), p.560-564
Main Authors: Kimple, Randall J, Harari, Paul M
Format: Article
Language:English
Subjects:
Alphapapillomavirus - isolation & purification
Applied radiobiology (equipment, dosimetry...)
Biological and medical sciences
Biological effects of radiation
Dose reduction
Fundamental and applied biological sciences. Psychology
Head and neck cancer
Head and Neck Neoplasms - radiotherapy
Head and Neck Neoplasms - virology
Hematology, Oncology and Palliative Medicine
Human papillomavirus
Humans
Medical sciences
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Otolaryngology
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Radiation
Radiotherapy Dosage
Tissues, organs and organisms biophysics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Patients with head and neck squamous cell carcinoma (HNC) related to human papillomavirus (HPV) represent a growing and distinct patient cohort with unique molecular and epidemiologic characteristics. These patients have markedly improved survival outcomes compared to those with traditional HNC, leading some to advocate for treatment dose reduction. In this article, we review ongoing clinical trials investigating several ways to reduce therapeutic intensity for patients with HPV-positive HNC, discuss the risks and benefits associated with these trials, and summarize the data underlying the advancement of dose reduction trials for patients with HPV-positive HNC.
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2013.09.015